leflunomide has been researched along with Acute Liver Injury, Drug-Induced in 35 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Methotrexate (MTX) and Leflunomide (LEF) combination has a better efficacy in the treatment of active rheumatoid arthritis (RA), but hepatotoxicity was observed." | 9.20 | Total glucosides of paeony can reduce the hepatotoxicity caused by Methotrexate and Leflunomide combination treatment of active rheumatoid arthritis. ( Chen, Z; Li, XM; Li, XP; Li, ZG; Su, Y; Xiang, N; Yang, M; Zhang, MJ; Zhao, DB; Zhu, P; Zuo, XX, 2015) |
| " In patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA), the incidence of elevated alanine aminotransferase/aspartate aminotransferase (ALT/AST) enzymes associated with methotrexate (MTX), leflunomide (LEF) and MTX+LEF versus other DMARDs was examined." | 7.76 | Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. ( Beukelman, T; Cassell, S; Curtis, JR; Greenberg, JD; Kavanaugh, A; Kremer, JM; Onofrei, A; Reed, G; Strand, V, 2010) |
| " Methotrexate (MTX) and Leflunomide (LEF) combination has a better efficacy in the treatment of active rheumatoid arthritis (RA), but hepatotoxicity was observed." | 5.20 | Total glucosides of paeony can reduce the hepatotoxicity caused by Methotrexate and Leflunomide combination treatment of active rheumatoid arthritis. ( Chen, Z; Li, XM; Li, XP; Li, ZG; Su, Y; Xiang, N; Yang, M; Zhang, MJ; Zhao, DB; Zhu, P; Zuo, XX, 2015) |
| "A 63-year-old Caucasian female patient with rheumatoid arthritis on methotrexate for 8 years and on leflunomide for 6 years was admitted for weakness, edema, ascites, and petechiae of the lower legs." | 3.96 | Thrombotic microangiopathy and liver toxicity due to a combination therapy of leflunomide and methotrexate: a case report. ( Girndt, M; Lübbert, C; Pliquett, RU; Schäfer, C, 2020) |
| " In patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA), the incidence of elevated alanine aminotransferase/aspartate aminotransferase (ALT/AST) enzymes associated with methotrexate (MTX), leflunomide (LEF) and MTX+LEF versus other DMARDs was examined." | 3.76 | Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. ( Beukelman, T; Cassell, S; Curtis, JR; Greenberg, JD; Kavanaugh, A; Kremer, JM; Onofrei, A; Reed, G; Strand, V, 2010) |
| "Leflunomide, a new immunomodulatory agent, was prescribed to a 67-year-old female patient with rheumatoid arthritis." | 3.72 | Leflunomide-induced acute hepatitis. ( Agúndez, JA; Díaz-Rubio, M; Fernández-Gutiérrez, B; Ladero, JM; Ortega, L; Sevilla-Mantilla, C, 2004) |
| "Spontaneous cases of hepatic adverse events have been reported in patients with rheumatoid arthritis who were being treated with leflunomide, one of the newer disease-modifying antirheumatic drugs (DMARDs)." | 3.72 | Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis. ( Bitton, A; Ernst, P; Hudson, M; Kezouh, A; Suissa, S, 2004) |
| "Leflunomide is a disease modifying anti-rheumatic drug (DMARD) beneficial in refractory cases of rheumatoid arthritis." | 1.51 | Leflunomide-induced liver injury in mice: Involvement of TLR4 mediated activation of PI3K/mTOR/NFκB pathway. ( El-Ghaiesh, SH; Elshaer, RE; Elsherbiny, NM; Nosseir, N; Tawfik, MK; Toraih, EA; Zaitone, SA, 2019) |
| "Leflunomide is an immunosuppressive agent marketed as a disease-modifying antirheumatic drug." | 1.43 | Inhibition of hepatic cytochrome P450 enzymes and sodium/bile acid cotransporter exacerbates leflunomide-induced hepatotoxicity. ( Cao, YY; Chen, C; Lin, YF; Luan, Y; Ma, LL; Ni, X; Pan, GY; Wang, J; Wang, L; Wu, ZT; Zhang, XF, 2016) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| " An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems." | 1.36 | Developing structure-activity relationships for the prediction of hepatotoxicity. ( Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010) |
| "Leflunomide has high hepatotoxic potential, especially when combined with methotrexate." | 1.36 | [Hepatotoxicity induced by new immunosuppressants]. ( Andrade, RJ; Cotta, J; Lucena, MA; Robles, M; Toscano, E, 2010) |
| "Acetaminophen (APAP) is safe at therapeutic levels but causes liver injury via N-acetyl-p-benzoquinone imine (NAPQI)-induced oxidative stress when overdose." | 1.35 | Prevention of acetaminophen (APAP)-induced hepatotoxicity by leflunomide via inhibition of APAP biotransformation to N-acetyl-p-benzoquinone imine. ( Chan, EC; New, LS; Tan, SC, 2008) |
| "Following repeated liver biopsy, autoimmune hepatitis was assumed and prednisolone and azathioprine were initiated." | 1.35 | [Elevated liver enzymes in rheumatoid arthritis : differential diagnostic considerations based on a case report]. ( Hartmann, U; Reuss-Borst, M; Schmitt, S, 2008) |
| "Leflunomide is a novel disease modifying antirheumatic drug (DMARD)." | 1.32 | Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity. ( Brouwers, JR; Houtman, NM; Jansen, TL; Spoelstra, P; van Roon, EN, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (28.57) | 29.6817 |
| 2010's | 21 (60.00) | 24.3611 |
| 2020's | 4 (11.43) | 2.80 |
| Authors | Studies |
|---|---|
| Fourches, D | 1 |
| Barnes, JC | 1 |
| Day, NC | 1 |
| Bradley, P | 1 |
| Reed, JZ | 1 |
| Tropsha, A | 1 |
| Greene, N | 1 |
| Fisk, L | 1 |
| Naven, RT | 1 |
| Note, RR | 1 |
| Patel, ML | 1 |
| Pelletier, DJ | 1 |
| Ekins, S | 1 |
| Williams, AJ | 1 |
| Xu, JJ | 1 |
| Chen, M | 2 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 3 |
| Dawson, S | 1 |
| Stahl, S | 2 |
| Paul, N | 1 |
| Barber, J | 1 |
| Kenna, JG | 2 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Warner, DJ | 1 |
| Chen, H | 1 |
| Cantin, LD | 1 |
| Walker, CL | 1 |
| Noeske, T | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Suzuki, A | 1 |
| Thakkar, S | 1 |
| Yu, K | 1 |
| Hu, C | 1 |
| Devarbhavi, H | 1 |
| Ghabril, M | 1 |
| Barnhart, H | 1 |
| Patil, M | 1 |
| Raj, S | 1 |
| Gu, J | 1 |
| Chalasani, N | 1 |
| Bonkovsky, HL | 1 |
| Sokar, SS | 1 |
| Alkabbani, MA | 1 |
| Akool, ES | 1 |
| Abu-Risha, SE | 1 |
| Elshaer, RE | 1 |
| Tawfik, MK | 1 |
| Nosseir, N | 1 |
| El-Ghaiesh, SH | 2 |
| Toraih, EA | 1 |
| Elsherbiny, NM | 1 |
| Zaitone, SA | 2 |
| Pliquett, RU | 1 |
| Lübbert, C | 1 |
| Schäfer, C | 1 |
| Girndt, M | 1 |
| Alamri, RD | 1 |
| Elmeligy, MA | 1 |
| Albalawi, GA | 1 |
| Alquayr, SM | 1 |
| Alsubhi, SS | 1 |
| Xuan, J | 1 |
| Ren, Z | 1 |
| Qing, T | 1 |
| Couch, L | 1 |
| Shi, L | 1 |
| Tolleson, WH | 1 |
| Guo, L | 1 |
| Huang, RY | 1 |
| Pan, HD | 1 |
| Wu, JQ | 1 |
| Zhou, H | 1 |
| Li, ZG | 2 |
| Qiu, P | 1 |
| Zhou, YY | 1 |
| Chen, XM | 1 |
| Xie, ZX | 1 |
| Xiao, Y | 1 |
| Huang, QC | 1 |
| Liu, L | 1 |
| Bilasy, SE | 1 |
| Essawy, SS | 1 |
| Mandour, MF | 1 |
| Ali, EA | 1 |
| Lin, KM | 1 |
| Cheng, TT | 1 |
| Lin, JC | 1 |
| Chen, CJ | 1 |
| Xiang, N | 1 |
| Li, XM | 1 |
| Zhang, MJ | 1 |
| Zhao, DB | 1 |
| Zhu, P | 1 |
| Zuo, XX | 1 |
| Yang, M | 1 |
| Su, Y | 1 |
| Chen, Z | 1 |
| Li, XP | 1 |
| Ma, LL | 1 |
| Wu, ZT | 1 |
| Wang, L | 1 |
| Zhang, XF | 1 |
| Wang, J | 1 |
| Chen, C | 1 |
| Ni, X | 1 |
| Lin, YF | 1 |
| Cao, YY | 1 |
| Luan, Y | 1 |
| Pan, GY | 1 |
| Goda, K | 1 |
| Takahashi, T | 1 |
| Kobayashi, A | 1 |
| Shoda, T | 1 |
| Kuno, H | 1 |
| Sugai, S | 1 |
| Tan, SC | 1 |
| New, LS | 1 |
| Chan, EC | 1 |
| Curtis, JR | 1 |
| Beukelman, T | 1 |
| Onofrei, A | 1 |
| Cassell, S | 1 |
| Greenberg, JD | 1 |
| Kavanaugh, A | 1 |
| Reed, G | 1 |
| Strand, V | 1 |
| Kremer, JM | 1 |
| Toscano, E | 1 |
| Cotta, J | 1 |
| Robles, M | 1 |
| Lucena, MA | 1 |
| Andrade, RJ | 1 |
| Gupta, R | 2 |
| Bhatia, J | 1 |
| Gupta, SK | 2 |
| Perdan-Pirkmajer, K | 1 |
| Hočevar, A | 1 |
| Rotar, Ž | 1 |
| Žibert, J | 1 |
| Marolt, VF | 1 |
| Gučev, F | 1 |
| Tomšič, M | 1 |
| Grove, ML | 1 |
| Yao, HW | 1 |
| Jin, Y | 1 |
| Li, J | 1 |
| Zhang, YF | 1 |
| Li, CY | 1 |
| Xu, SY | 1 |
| Sevilla-Mantilla, C | 1 |
| Ortega, L | 1 |
| Agúndez, JA | 1 |
| Fernández-Gutiérrez, B | 1 |
| Ladero, JM | 1 |
| Díaz-Rubio, M | 1 |
| van Roon, EN | 1 |
| Jansen, TL | 1 |
| Houtman, NM | 1 |
| Spoelstra, P | 1 |
| Brouwers, JR | 1 |
| Suissa, S | 1 |
| Ernst, P | 1 |
| Hudson, M | 1 |
| Bitton, A | 1 |
| Kezouh, A | 1 |
| Suzuki, Y | 1 |
| Saito, E | 1 |
| Wakabayashi, T | 1 |
| Suwa, A | 1 |
| Hartmann, U | 1 |
| Schmitt, S | 1 |
| Reuss-Borst, M | 1 |
| Breedveld, FC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-Center, Longitudinal Study of Drug-and CAM-Induced Liver Injury[NCT00345930] | 4,000 participants (Anticipated) | Observational | 2004-09-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for leflunomide and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Pr | 2016 |
Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: A comprehensive review.
Topics: Antineoplastic Agents; Antiviral Agents; Chemical and Drug Induced Liver Injury; Clinical Trials as | 2021 |
[Adverse effects of conventional DMARDs and biologic DMARDs].
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Chemical and Drug Induced Liver Injury; Cysteine; Drug | 2007 |
3 trials available for leflunomide and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
Comparison of combination therapy with methotrexate and sinomenine or leflunomide for active rheumatoid arthritis: A randomized controlled clinical trial.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Chemical and Drug Induced Liver Injury; Drug The | 2019 |
Total glucosides of paeony can reduce the hepatotoxicity caused by Methotrexate and Leflunomide combination treatment of active rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Chemical and Drug Induced | 2015 |
Risk of hepatotoxicity with add-on leflunomide in rheumatoid arthritis patients.
Topics: Adult; Aged; Alanine Transaminase; Antirheumatic Agents; Arthritis, Rheumatoid; Aspartate Aminotrans | 2011 |
29 other studies available for leflunomide and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLI | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2012 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Leflunomide-induced liver injury: Differences in characteristics and outcomes in Indian and US registries.
Topics: Chemical and Drug Induced Liver Injury; Chemical and Drug Induced Liver Injury, Chronic; Drug-Relate | 2022 |
Hepatoprotective effects of carvedilol and crocin against leflunomide-induced liver injury.
Topics: Animals; Carvedilol; Catalase; Chemical and Drug Induced Liver Injury; Chemical and Drug Induced Liv | 2022 |
Leflunomide-induced liver injury in mice: Involvement of TLR4 mediated activation of PI3K/mTOR/NFκB pathway.
Topics: Animals; Caspase 3; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Leflun | 2019 |
Thrombotic microangiopathy and liver toxicity due to a combination therapy of leflunomide and methotrexate: a case report.
Topics: Arthritis, Rheumatoid; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Female; Hu | 2020 |
Mitochondrial dysfunction induced by leflunomide and its active metabolite.
Topics: Adenosine Triphosphate; Anti-Inflammatory Agents, Non-Steroidal; Bongkrekic Acid; Chemical and Drug | 2018 |
Myelosuppressive and hepatotoxic potential of leflunomide and methotrexate combination in a rat model of rheumatoid arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Blood | 2015 |
Tumor necrosis factor-α antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study.
Topics: Adalimumab; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumato | 2015 |
Inhibition of hepatic cytochrome P450 enzymes and sodium/bile acid cotransporter exacerbates leflunomide-induced hepatotoxicity.
Topics: Animals; Antirheumatic Agents; Cells, Cultured; Chemical and Drug Induced Liver Injury; Crotonates; | 2016 |
Usefulness of in vitro combination assays of mitochondrial dysfunction and apoptosis for the estimation of potential risk of idiosyncratic drug induced liver injury.
Topics: Acetaminophen; Apoptosis; Biological Assay; Biomarkers; Caspase 3; Caspase 7; Cells, Cultured; Chemi | 2016 |
Prevention of acetaminophen (APAP)-induced hepatotoxicity by leflunomide via inhibition of APAP biotransformation to N-acetyl-p-benzoquinone imine.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Antirheumatic Agents; Benzoquinones; Biotransforma | 2008 |
Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis | 2010 |
[Hepatotoxicity induced by new immunosuppressants].
Topics: Azathioprine; Chemical and Drug Induced Liver Injury; Cyclosporine; Humans; Immunosuppressive Agents | 2010 |
Tumour necrosis factor-alpha inhibitor-induced hepatic injury in patients with rheumatoid arthritis: two case reports and an analysis of the laboratory data from the Slovenian national biologicals registry.
Topics: Adalimumab; Adult; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; B | 2013 |
US Food and Drug Administration gets it right.
Topics: Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Cyclooxygenase 2; Drug Approval; Hu | 2002 |
[Effects of leflunomide on immunological liver injury].
Topics: Adjuvants, Immunologic; Animals; Cell Division; Chemical and Drug Induced Liver Injury; Interleukin- | 2001 |
Leflunomide-induced acute hepatitis.
Topics: Adjuvants, Immunologic; Aged; Anion Exchange Resins; Arthritis, Rheumatoid; Chemical and Drug Induce | 2004 |
Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Chemical and Drug Induced Liver Injury; Female | 2004 |
Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; C | 2004 |
Severe hepatotoxicity in a rheumatoid arthritis patient switched from leflunomide to methotrexate.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Chemical and Drug Induced Liver Injury; Female; | 2005 |
[Elevated liver enzymes in rheumatoid arthritis : differential diagnostic considerations based on a case report].
Topics: Adalimumab; Adolescent; Alanine Transaminase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humani | 2008 |
Is there a place for leflunomide in the treatment of rheumatoid arthritis?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Liver Inju | 2001 |